Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:Ninjutsu
|
| gptkbp:activities |
inhibits trypanothione reductase
|
| gptkbp:appointed_by |
intravenous injection
|
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
Arsobal
|
| gptkbp:café |
6320
|
| gptkbp:clinical_trial |
Phase II
Phase III |
| gptkbp:composed_of |
derived from arsenic
|
| gptkbp:contraindication |
severe renal impairment
severe liver impairment |
| gptkbp:developed_by |
gptkb:WHO
|
| gptkbp:discovered_by |
1940s
|
| gptkbp:dissolved |
soluble in water
soluble in ethanol |
| gptkbp:duration |
7 days
|
| gptkbp:enemy |
CHEMB L1201150
|
| https://www.w3.org/2000/01/rdf-schema#label |
melarsoprol
|
| gptkbp:ingredients |
C12 H12 N2 O4 S
|
| gptkbp:interacts_with |
may interact with anticoagulants
may interact with anticonvulsants may interact with other antimalarials may interact with antiretrovirals |
| gptkbp:is_atype_of |
P01 C C01
|
| gptkbp:is_monitored_by |
liver function tests
complete blood count renal function tests neurological status |
| gptkbp:is_used_for |
gptkb:African_sleeping_sickness
|
| gptkbp:level |
7.5
|
| gptkbp:lifespan |
1-2 hours
|
| gptkbp:manager |
IV
|
| gptkbp:marketed_as |
gptkb:Sanofi
|
| gptkbp:monitors |
0 A2 D1 F1 B2 B
|
| gptkbp:name |
Essential Medicines
|
| gptkbp:rounds |
renal
|
| gptkbp:safety_features |
Category C
|
| gptkbp:side_effect |
headache
nausea fever vomiting neurotoxicity hypersensitivity reaction cardiovascular effects encephalopathy hematological effects |
| gptkbp:treatment |
antiparasitic therapy
stage 2 Trypanosomiasis |
| gptkbp:type_of |
60-29-7
|